Neurocrine Biosciences (NBIX) Liabilities and Shareholders Equity (2010 - 2026)

Neurocrine Biosciences has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $4.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 33.04% year-over-year to $4.9 billion; the trailing twelve-month figure through Mar 2026 stood at $17.7 billion (up 24.19% YoY), and the FY2025 full-year result was $4.6 billion, up 24.55% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $4.9 billion, up from $4.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $4.9 billion in Q1 2026, with the low at $2.0 billion in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $3.2 billion across 5 years, with a median of $3.3 billion in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity climbed 2.52% — and 2024, when it soared 47.15%.
• Neurocrine Biosciences' Liabilities and Shareholders Equity stood at $2.4 billion in 2022, then soared by 37.27% to $3.3 billion in 2023, then gained by 14.37% to $3.7 billion in 2024, then increased by 24.55% to $4.6 billion in 2025, then grew by 5.93% to $4.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $4.9 billion (Q1 2026), $4.6 billion (Q4 2025), and $4.3 billion (Q3 2025), per Business Quant data.